The Committee discusses Eli Lilly & Co., Biologics License Application #761248 for Donanemab solution for intravenous infusion for the treatment of early symptomatic Alzheimer’s disease in a meeting being held in Silver Spring, MD on June 10 at 9 am. Webcast Link
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LLY:
- FDA releases documents ahead of panel review of Eli Lilly’s donanemab
- Jefferies doesn’t think GLP-1s will eliminate Madrigal opportunity in NASH
- Alphabet investors will ‘look positively’ on CFO appointment, says Jefferies
- Madrigal, 89bio, Akero slip after Eli Lilly MASH data released
- Eli Lilly CFO Anat Ashkenazi Resigns, Search for Successor Begins